Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 141 clinical trials
Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is a phase

  • 6 views
  • 02 Jun, 2022
  • 1 location
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer

The purpose of this study is to assess the safety and efficacy of alpelisib plus fulvestrant in men and postmenopausal women with hormone receptor (HR) positive, human epidermal growth factor 2

aromatase inhibitor
fulvestrant
measurable disease
PIK3CA
her2-negative breast cancer
  • 0 views
  • 09 Aug, 2022
  • 9 locations
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer (PEER)

advanced or metastatic hormonal receptor positive (HR+)/ Human epidermal growth factor receptor 2 (HER2) negative breast cancer. All the patients will be included in the final tolerability and preliminary

  • 2 views
  • 06 Feb, 2022
  • 1 location
A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

In this study, researchers want to learn about the safety of drug BAY2701439 and how well the drug works in patients with advanced cancer that has the protein HER2 (Human Epidermal growth factor

  • 2 views
  • 11 Aug, 2022
  • 6 locations
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1)

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in patients with advanced cancer that has recurred/progressed.

  • 0 views
  • 29 Jul, 2022
  • 2 locations
Ribociclib and Letrozole Treatment in Ovarian Cancer

The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.

  • 164 views
  • 26 Mar, 2022
  • 27 locations
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

Primary Objective: To examine the impact of Circulating tumor DNA (ctDNA) (expressed as mean tumor molecules per ml) on treatment decision making in patients with early stage breast cancer after neoadjuvant therapy and surgery Secondary Objectives: Understand ctNDA kinetics in the neoadjuvant and adjuvant setting To identify any associations between …

  • 0 views
  • 14 May, 2022
  • 9 locations
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA)

Hormone Receptor (HR)-positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative advanced breast cancer (ABC)

letrozole
liquid biopsy
growth factor
aromatase inhibitor
EGFR
  • 90 views
  • 30 Apr, 2022
  • 51 locations
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)

This study will evaluate the efficacy, safety and patient-reported outcomes of trastuzumab emtansine plus atezolizumab compared with trastuzumab emtansine plus placebo in participants with HER2-positive and PD-L1-positive LABC or MBC.Participants must have progressed either during or after prior trastuzumab- (+/- pertuzumab) and taxane-based therapy for LABC/MBC; or during (or within …

  • 0 views
  • 07 Jul, 2022
  • 120 locations
A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

locally advanced or metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-expressing cancers.

cancer
oxaliplatin
fluorouracil
solid tumor
HER2
  • 41 views
  • 25 Jul, 2022
  • 25 locations